semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Organophosphate Poisoning Male (females usually wear national dresses considered to provide adequate protection (43) Age min. 18 years (implies being a legal worker) Grows crops in knee and abdomen height in given data collection period Willing to spend 1.5-3 hours working with organophosphates under normal working conditions Involved in farming minimum two years (implies being active) Usually sprays at least once in two weeks with organophosphates on average (implies being active) Uses a hand pressured backpack sprayer placed at home (necessary to complete non-intervention) Works with crops in 5-10 katha land (sufficient to apply organophosphates for given time) Has a mobile/landline number (necessary for easy contact) Has a helper during work with organophosphates (organophosphate exposure reduced)
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 15.0-60.0,  Postoperative Ileus Patients of either gender with age ranging from 15 to 60 years. 2. Patients whose ileostomies were made for typhoid or tuberculous perforation 3. Patients with no distal obstruction on loopogram  Patients with age less than 15 years and greater than 60. 2. Patients having co-morbid factors such as diabetes and ischemic heart disease. 3. Patients whose ileostomy was made for any condition other than typhoid or tuberculosis
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 0.25-10.0,  Acute Gastroenteritis Children aged 3 months to 10 years with recent significant vomiting and moderate dehydration who are managed according to the Alberta Health Services (Calgary and Area) Acute Childhood Vomiting & Diarrhea Pathway The following definitions are used to determine according to the pathway: Recent, significant vomiting Vomiting at least 6 episodes in the past 6 hours and at least once in the past hour; Moderate dehydration (Gorelick Score 2) Two of the following: capillary refill time greater than 2 seconds, absence of tears, dry mucous membranes, ill general appearance  Children who are excluded from the Alberta Health Services (Calgary and Area) Acute Childhood Vomiting & Diarrhea Pathway These Vomiting or Diarrhea for greater than 7 days, Localized abdominal pain, Chronic medical conditions affecting major organ systems (Ex, diabetes, PKU, immunodeficiency), Likely GI Obstruction (abdominal distension, bilious vomiting, absent bowel sounds), Weight less than 8kg. Children who have received anti-emetics at home will not be excluded but will be tracked
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Abdominal Infection Be consistent with severe sepsis and septic shock diagnosis standards Age above 18 years old, is expected in more than 5 days in ICU score>15 By the patients themselves or their authorized person agreed to participate in the clinical trial and signed the informed consent  Allergic to penicillin, or of tigecycline allergic patients Patients with abnormal liver function is severe Be pregnant or lactating women Be not signed the informed consent of patients Any can be expected to increase patient risk or other factors can interfere with the results of a clinical trial
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 21.0-50.0,  Healthy Participants should be healthy males and females Age range from 21 to 50 years Broca Index: within 20% of their normal weight All female volunteers must use a safe contraception (i.e. oral contraception, spiral, sterilized) All female volunteers must have a negative pregnancy test Prior to admission to the treatment after giving his/her informed consent (in accordance with Good Clinical Practice (GCP) and local legislation) in writing each subject will have his medical history taken and will receive a complete medical examination (incl. blood pressure and pulse rate measurements) as well as a 12-lead ECG within 14 days before the administration of the test substance. Hematopoietic, hepatic and renal function test will be carried out in the laboratory. The subjects will fast for 12 hours before collection of specimens for all laboratory evaluations  Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Diseases of the central nervous system (such as epilepsy) or with psychiatric disorders or neurological disorders History of orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator Intake of a drug with a long half-life (>= 24 hours) within ten half-lives of the respective drug before enrolment in the study or during the study Use of any drugs which might influence the results of the trial within two weeks prior to administration or during the trial Participation in another study with an investigational drug within two months prior to administration or during the trial Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day)
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Type 2 Diabetes Body mass index (BMI) 27-37 kg/m2 Male Age 18-60 years old Type 2 diabetes mellitus reasonably well controlled (HbA1c less than or equal to 58 mmol/mol) on diet therapy or metformin alone Not taking anti-diabetes medication other than metformin Understand verbal and/or written explanation of the study requirements  Malignancy (excluding localised basal and squamous cell skin cancer) Metabolic diseases (stable treated hypothyroidism allowed) Active cardiovascular disease (current angina, myocardial infarct, or coronary artery surgery/angioplasty within 12 months) Primary muscle disorders Cerebrovascular disease Neurological disease e.g. epilepsy, Parkinsons disease Active respiratory disease Active gastrointestinal or liver disease Renal impairment (eGFR <60 ml/min) Clotting dysfunction
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Pancreatitis clinical diagnosis of acute pancreatitis，both mild type and severe type  pregnant or suckling cancer in late time patient near death
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Diabetes Endothelial Dysfunction Men and women with type 2 diabetes who are treated with oral hypoglycemic agents at a stable dose for at least 8 weeks have diabetes diagnosed >6 months have maintained stable weight for 2 months (within 3%) have a valid Ontario Health Insurance Plan (OHIP) card and a family physician if prescribed lipid medication, have taken a stable dose for at least 2 weeks if prescribed blood pressure medication, have taken a stable dose for at least 1 week can keep written food records carotid intima-media thickness (cIMT) < 1.2 mm and ankle brachial index (ABI) of >0.9  Individuals who take insulin take steroids have GI disease (gastroparesis, celiac disease, ulcerative colitis, Crohn's Disease, IBS) have had a major cardiovascular event (stroke or myocardial infarction) in the past 6 months take warfarin (Coumadin) have had major surgery in the past 6 months have a major debilitating disorder have clinically significant liver disease ( liver transaminase levels > 130 U/L), excluding Nonalcoholic fatty liver (NAFL) disease or NASH have hepatitis B or C
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 35.0-80.0,  Healthy Subjects Pharmacokinetics of ASP8232 Pharmacodynamics of ASP8232 Chronic Kidney Disease (CKD) Type 2 Diabetes Mellitus (T2DM) Main Part 1 Independent Ethics Committee (IEC)-approved written Informed Consent and privacy language as per national regulations must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable) Male subject and his female spouse/partner who is of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at screening and continue throughout the study period and for 28 days (or 5 half-lives of the study drug whichever is longer) after final study drug administration Male subject must not donate sperm starting at screening and throughout the study period and for at least 90 days after final study drug administration Female subject must be either post-menopausal (defined as at least one year without any menses) prior to screening, or premenarchal prior to screening, or documented surgically sterile or status post hysterectomy (at least 1 month before screening), or if of childbearing potential, must have a negative urine pregnancy test at screening and must be using highly effective contraception. All females of childbearing potential will be required to use highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at screening and throughout the study period and for 28 days (or 5 half-lives of the study drug whichever is longer) after final study drug administration Female subject must not be lactating, and must not be breast feeding at screening or during the study period and for 28 days [or 5 half-lives of the study drug whichever is longer] after final study drug administration
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Diverticulitis Diverticulosis Diverticular Disease Groups A and B. Patients with acute diverticulitis patients presenting to A&E at King's College Hospital with new onset abdominal pain, with or without a known diagnosis of diverticulitis Groups C and D. Patients with asymptomatic diverticulosis and normal controls Patients being assessed through the 2ww Colorectal Cancer pathway with a chief complaint of fresh PR bleeding and no other 'red flag' symptoms, who are not overly anxious over their diagnosis as assessed by a physician outside the study team  Groups A and B. Patients with acute diverticulitis Patients in extremis e.g. systolic blood pressure less than 80 on arrival or pulse greater than 115 Patients who have received antibiotics in the three months prior to presentation Vulnerable patient populations Groups C and D. Patients with asymptomatic diverticulosis and normal controls Patients with high levels of pre-test anxiety, as determined by their assessing physician, outside the study team Patients who received antibiotics for any reason in the 3 months prior to Vulnerable patient populations
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Pancreatitis Acute pancreatitis Hospitalisation Adult patients  Recurrent pancreatitis Chronic pancreatitis Outpatient follow up Loss of follow up within 3 months of discharge
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Diabetes Mellitus Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial Male or female aged 18-65 years (both inclusive) T2DM diagnosis  Contraindications (including known or suspected hypersensitivity) to GLP-1 mimetics Use of GLP-1 mimetics or DPP-IV inhibitors Clinically relevant dysglycaemia as indicated by HbA1C ≥ 10%
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Tobacco Use Disorder Male or Female Ages 18-70 Past-year major depressive disorder, dysthymic disorder, generalized anxiety disorder, post-traumatic stress disorder, obsessive-compulsive disorder, phobia, or panic disorder with or without agoraphobia, based on MINI structured interview, OR lifetime diagnosis of one of the above based on MINI with a self-report of currently receiving treatment (prescribed psychoactive medication, behavioral therapy, etc.) Report smoking 5 or more cigarettes per day for the past year Provide an intake breath CO sample > 8 ppm Be without current substance abuse/dependence other than nicotine Be sufficiently literate to complete the research-related tasks Be in good physical health without serious illness or change in health in the past 3 months as determined by the licensed medical professional at each site Not pregnant or nursing and report using oral, implant, patch, ring, IUD, injection or barrier contraceptives or report being surgically sterile or post-menopausal Report no significant use of other tobacco or nicotine products within the past month (> 9 days in the past 30)  Any prior regular use (used as primary cigarette outside of the laboratory) of Spectrum cigarettes (i.e., research cigarettes with reduced nicotine content) Exclusive use of roll-your-own cigarettes Planning to quit smoking in the next 30 days A quit attempt in the past 30 days resulting in > 3 days of abstinence Positive toxicology screen for illicit drugs not including marijuana (participants with valid prescriptions will not be excluded and participants with a positive toxicology screen will be allowed to re-screen once) Breath alcohol level > 0.01 (participants with a positive screen will be allowed to re-screen once) Self-report of binge drinking alcohol (> 9 days in the past 30, 4/5 drinks in 2 hours for women/men Systolic blood pressure below 90 mmHg or greater than or equal to 160 mmHg (participants outside the range will be allowed to re-screen once) Diastolic blood pressure below 50 mmHg or greater than or equal to 100 mmHg (participants outside the range will be allowed to re-screen once) Breath CO > 80 ppm